Vanflyta (quizartinib)
- Region
- 🇪🇺 EU
- Active substance
- quizartinib
- Company
- Daiichi Sankyo Europe GmbH
- Status
- Refused
- Therapeutic area
- Leukemia, Myeloid, Acute
- CHMP opinion
- Thu 17 Oct 2019
- Application
- EMEA/H/C/004468
- ATC
- L01XE
- Official record
- www.ema.europa.eu
Indication
Treatment of acute myeloid leukaemia.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Vanflyta Authorised · Daiichi Sankyo Europe GmbH
Follow Vanflyta
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.